Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Bevacizumab in Nonsquamous Lung Cancer

November 11th 2016

Targeting Angiogenesis in Non–Small Cell Lung Cancer

November 11th 2016

Dysregulated Angiogenesis in Lung Cancer

November 11th 2016

Dr. Patrick M. Forde on Next Steps After CheckMate-026 Study in NSCLC

November 11th 2016

Patrick M. Forde, MBBCh, assistant professor of oncology, Johns Hopkins Hospital, discusses the CheckMate-026 study, which demonstrated that first-line therapy with nivolumab failed to improve progression-free survival (PFS) in PD-L1–positive non-small cell lung cancer (NSCLC) compared with standard chemotherapy.

Dr. Alice T. Shaw on Ceritinib for Frontline ALK+ NSCLC With Brain Metastases

November 4th 2016

Alice T. Shaw, MD, PhD, thoracic oncologist at the Massachusetts General Hospital Cancer Center, discusses ceritinib in newly diagnosed patients with ALK-positive non-small cell lung cancer (NSCLC) and brain metastases.

Dr. David L. Rimm on the Continued Role for PD-L1 Testing in NSCLC

November 3rd 2016

David L. Rimm, MD, PhD, professor of pathology and of medicine, director of pathology tissue services, director of translational pathology, Yale Cancer Center, discusses the continued role for PD-L1 testing to predict response with checkpoint inhibitors in non–small cell lung cancer (NSCLC).

Dr. DeCamp on Platforms of Surgical Management in Lung Cancer

November 2nd 2016

Malcolm McAvoy DeCamp, Jr, MD, chief of Thoracic Surgery in the Department of Surgery, Northwestern University Feinberg School of Medicine, discusses different platforms of surgical management in the treatment of patients with lung cancer.

The Future of Non-Driver Lung Adenocarcinoma

October 31st 2016

Cost Considerations in Non-Driver NSCLC Management

October 31st 2016

Nintedanib in Lung Adenocarcinoma: Managing Toxicities

October 31st 2016

Practical Considerations With Nintedanib in Lung Adenocarcinoma

October 31st 2016

Practical Implications of the LUME-Lung 1 Findings

October 31st 2016

Lung Adenocarcinoma: Patient Selection With Ramucirumab vs Nintedanib

October 31st 2016

Differentiating Among Anti-VEGF Therapies in Lung Adenocarcinoma

October 31st 2016

Non-Driver NSCLC: Clinical Decisions in Rapidly Progressing Disease

October 31st 2016

PD-L1 Status in Second-Line Lung Adenocarcinoma

October 31st 2016

Options in Second-Line Non-Squamous NSCLC

October 31st 2016

Potential Upfront and Maintenance Strategies in NSCLC

October 31st 2016

Non-Driver Mutation Non-Squamous NSCLC

October 31st 2016

First-Line Chemotherapy Options in Lung Adenocarcinoma

October 31st 2016